256 related articles for article (PubMed ID: 24257371)
21. Antitumor effect of endostatin overexpressed in C6 glioma cells is associated with the down-regulation of VEGF.
Yang L; Lin Z; Lin J; Weng S; Huang Q; Zhang P; Fu J
Int J Oncol; 2011 Feb; 38(2):465-71. PubMed ID: 21165557
[TBL] [Abstract][Full Text] [Related]
22. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma.
de Groot J; Liang J; Kong LY; Wei J; Piao Y; Fuller G; Qiao W; Heimberger AB
Oncotarget; 2012 Sep; 3(9):1036-48. PubMed ID: 23013619
[TBL] [Abstract][Full Text] [Related]
23. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
[TBL] [Abstract][Full Text] [Related]
24. In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model.
Pasco S; Ramont L; Venteo L; Pluot M; Maquart FX; Monboisse JC
Exp Cell Res; 2004 Dec; 301(2):251-65. PubMed ID: 15530861
[TBL] [Abstract][Full Text] [Related]
25. Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma.
Barone A; Sengupta R; Warrington NM; Smith E; Wen PY; Brekken RA; Romagnoli B; Douglas G; Chevalier E; Bauer MP; Dembowsky K; Piwnica-Worms D; Rubin JB
Oncotarget; 2014 Oct; 5(20):9811-22. PubMed ID: 25238146
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
27. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
[TBL] [Abstract][Full Text] [Related]
30. Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway.
Fu J; Zhu SH; Xu HB; Xu YQ; Wang X; Wang J; Kong PS
J Ethnopharmacol; 2020 Oct; 261():113071. PubMed ID: 32603676
[TBL] [Abstract][Full Text] [Related]
31. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin.
Maeshima Y; Manfredi M; Reimer C; Holthaus KA; Hopfer H; Chandamuri BR; Kharbanda S; Kalluri R
J Biol Chem; 2001 May; 276(18):15240-8. PubMed ID: 11278365
[TBL] [Abstract][Full Text] [Related]
32. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo.
Bello L; Carrabba G; Giussani C; Lucini V; Cerutti F; Scaglione F; Landré J; Pluderi M; Tomei G; Villani R; Carroll RS; Black PM; Bikfalvi A
Cancer Res; 2001 Oct; 61(20):7501-6. PubMed ID: 11606386
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Golubovskaya VM; Huang G; Ho B; Yemma M; Morrison CD; Lee J; Eliceiri BP; Cance WG
Mol Cancer Ther; 2013 Feb; 12(2):162-72. PubMed ID: 23243059
[TBL] [Abstract][Full Text] [Related]
34. Tumstatin transfected into human glioma cell line U251 represses tumor growth by inhibiting angiogenesis.
Ye HX; Yao Y; Jiang XJ; Yuan XR
Chin Med J (Engl); 2013; 126(9):1720-5. PubMed ID: 23652057
[TBL] [Abstract][Full Text] [Related]
35. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
36. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development.
Hong YK; Chung DS; Joe YA; Yang YJ; Kim KM; Park YS; Yung WK; Kang JK
Clin Cancer Res; 2000 Aug; 6(8):3354-60. PubMed ID: 10955823
[TBL] [Abstract][Full Text] [Related]
37. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
38. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
[TBL] [Abstract][Full Text] [Related]
39. Prolactin and its receptor as therapeutic targets in glioblastoma multiforme.
Asad AS; Nicola Candia AJ; Gonzalez N; Zuccato CF; Abt A; Orrillo SJ; Lastra Y; De Simone E; Boutillon F; Goffin V; Seilicovich A; Pisera DA; Ferraris MJ; Candolfi M
Sci Rep; 2019 Dec; 9(1):19578. PubMed ID: 31862900
[TBL] [Abstract][Full Text] [Related]
40. Enhanced cancer therapy with the combination of EGFR and VEGFR-2 targeting in an orthotopic glioblastoma model.
Diao Y; Tian XH; Huang YL; Chen LK; Lin XN; Zhuang ZW
J Chemother; 2010 Dec; 22(6):407-12. PubMed ID: 21303749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]